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Objective: The aim of this study was to assess the effect of V3 fatty acids
(V3FA) on fatty and lean liver in hepatic surgery.
Background: The global spread of energy-dense diets has led to an endemic
rise in fatty liver disease and obesity. Besides metabolic pathologies, steatosis
enhances hepatic sensitivity to ischemia reperfusion (I/R) and impedes liver
regeneration (LR). Steatosis limits the application of liver surgery, still the
main curative option for liver cancer.V3FA are known to reverse steatosis, but
how these lipids affect key factors defining surgical outcomes—that is, I/R,
LR, and liver malignancy—is less clear.
Methods: We established a standardizedmousemodel of high fat diet (HFD)-
induced steatosis followed byV3FA treatment and the subsequent assessment
of V3FA effects on I/R, LR, and liver malignancy (n ¼ 5/group), the latter
through a syngeneic metastasis approach. Fatty liver outcomes were com-
pared with lean liver to assess steatosis-independent effects. Nonparametric
statistics were applied.
Results: V3FA reversed HFD-induced steatosis and markedly protected
against I/R, improved LR, and prolonged survival of tumor-laden mice.
Remarkably, these beneficial effects were also observed in lean liver, albeit
at a smaller scale. Notably, mice with metastases in fatty versus lean livers
were associated with improved survival.
Conclusions: V3FA revealed multiple beneficial effects in fatty and lean
livers in mice. The improvements in I/R injury, regenerative capacity, and
oncological outcomes await confirmatory studies in humans.
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(Ann Surg 2016;xx:xxx–xxx)
From the Swiss HPB and Transplantation Center, University Hospital Zurich,
Zurich, Switzerland; yDepartment of Cellular Physiology and Metabolism,
Faculty of Medicine, University of Geneva, Geneva, Switzerland; and
zHepatology Unit, Department of Clinical Research, University Hospital Bern,
Bern, Switzerland.
Reprints: Pierre-Alain Clavien, MD, PhD, Department of Surgery, University
Hospital Zurich, Raemistrasse 100, CH-8091 Zurich, Switzerland.
E-mail: clavien@access.uzh.ch.
ML, BH, MF, JFD did the experimental design. ML, PL, PKa, PKr, CT, NC did the
data acquisition and analyses. BH, ML, MF, JFD, RG did the data interpret-
ation. BH, ML did the study concept and design. BH, ML, PAC did the
manuscript writing and critical revision. BH, PAC provided funding for this
study. All authors approved the final version.
Bostjan Humar and Pierre-Alain Clavien shared senior authorship.
The project was supported by grants from the Sinergia grant from the Swiss
National Science Foundation 310030B_150042 and CRSII3_141798/1, from
the Clinical Research Priority Program University of Zurich (CRPP Liver
Tumors) and from the Liver and Gastrointestinal Disease Foundation (LGID).
All authors contributing to this manuscript declare that they have nothing to
disclose. They do not have a conflict of interest with respect to this manuscript.
Supplemental digital content is available for this article. Direct URL citations
appear in the printed text and are provided in the HTML and PDF versions of
this article on the journal’s Web site (www.annalsofsurgery.com).
Copyright  2016 Wolters Kluwer Health, Inc. All rights reserved.
ISSN: 0003-4932/14/26105-0821
DOI: 10.1097/SLA.0000000000001968
Annals of Surgery  Volume XX, Number X, Month 2016
Copyright © 2016 Wolters Kluwer Health, Inc. Uand Pierre-Alain Clavien, MD, PhD
T he increasing consumption of fat-laden diets is putting a strain onthe liver. Many societies experience an endemic rise in obesity
and the metabolic syndrome (MS), often already apparent in children
and young adults.1 Nonalcoholic fatty liver disease (NAFLD) is the
hepatic manifestation of the MS and is thought to underlie its
hallmark insulin resistance and its associated cardiovascular risks.2
Surgical removal remains the only curative option for liver
tumors with an increased risk of liver failure in the presence of
hepatic steatosis.3 To prevent blood loss during liver resection, portal
inflow is temporarily occluded, leading to an ischemic period that
may cause significant liver injury upon reperfusion. Steatosis not
only enhances the liver’s sensitivity toward ischemic insults but also
impedes its regenerative capacity in terms of both repairing ischemic
injury and compensating for lost volume following resection.4,5
Together, these features lead to an elevated rate of postoperative
complications that restrict surgical options in patients with fatty liver.5
Simple and well-tolerated means to negate the impact of liver
fat on surgical outcomes are highly desired. Omega-3 polyunsatu-
rated fatty acids (V3FA), most known for their potential benefits to
cardiovascular health,6 may combine many properties sought for
liver surgery. Although mechanisms underlying V3FA action are
incompletely understood, observations such as the coupling of
enhanced energy turnover with anti-inflammatory mechanisms are
likely related to the potent anti-steatotic effects described for V3FA
in liver.7–9 Of note, V3FA have been reported to suppress steatosis
also in a mouse model of diet-induced obesity10 and in NAFLD
patients.11 The anti-inflammatory properties of V3FA further trans-
late into an efficient protection of animal liver from ischemia-
reperfusion (I/R) injury. We have shown that V3FA reduce I/R
injury in lean mouse liver via engagement of Gpr120, which imprints
an anti-inflammatory M2 polarization phenotype onto Kupffer
cells.12 Likewise, V3FA were also effective against I/R in the ob/
obmodel of NAFLD.13 In addition,V3FA seem to improve recovery
of lean liver from resection-induced liver failure, or of fatty liver after
standard resection.14,15 Whether such effects are indirect (eg, by
protecting from injury) or direct (eg, by promoting hepatocyte
proliferation) remains unclear, but the resulting benefits can also
be observed in the clinic.16 Finally, V3FA have been associated with
anti-cancerous properties in a variety of neoplasms.17 The effects of
V3FA on colorectal liver metastasis (CRLM)—the most common
indication for liver surgery in the Western world—are unclear. In a
syngeneic rat model, V3FA promoted CRLM development, while in
another study—based on the same rats and cancer cells—V3FA
revealed beneficial effects.18,19
The effects on steatosis, hepatic I/R, liver recovery after
resection, and liver tumors together suggest a fallow potential of
V3FA to improve outcomes in liver surgery. What remains unknown
is (i) whether V3FA’s beneficial effects are simply due to fat
reduction, (ii) whether V3FA can directly promote parenchymal
regeneration after resection, and (iii) whether V3FA do counteract
the formation or growth of liver tumors, particularly in a fatty
background. Moreover, it is not established whether the single effects
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To address these questions, we designed a standardized mouse model
of fatty liver surgery based on a high fat diet (HFD). This model
enabled us to study the effects of dietaryV3FA on steatosis, I/R, liver
regeneration, and tumor risk in the settings of pre-existing NAFLD
compared with a lean background. Our findings strongly encourage
the pre-operative use of V3FA to expand the application of surgery
for fatty liver.
METHODS
Animals and Diets
All animal experiments were approved by the Veterinary Office
of Zurich, Switzerland. Male mice (C57BL6, Harlan) were purchased
at the age of 8 to 10weeks and kept on a 12-hour day/night cycle. After
accommodation for 1week, animalswere either exposed toHFD (total
energy 22MJ/kg, 60kJ% from fat and 8.4 kJ% sucrose) or a control
diet (CD, total energy 15MJ/kg, 11 kJ% from fat without sucrose) for
6 weeks (ssniff, Soest, Germany). During treatment, overall calories in
HFD were reduced by 3MJ/kg to mimic mild pre-operative calorie
restriction, and forV3FA treatment, fish oil (mainly eicosapentaenoic
acid, EPA, and docosahexaenoic acid, DHA) replaced 45% of total fat
while maintaining 8.4 kJ% sucrose (Supplementary Figure 1A, http://
links.lww.com/SLA/B84). Each treatment group included 5 animals,
with a total of 180 animals used for the experimental setup.
Lipid Quantification Using Small Animal MRI and
Chemical Analysis
To assess liver fat content longitudinally in vivo, a small-
animal 4.7-Tesla magnetic resonance imaging (MRI) scanner
(Bruker BioSpin MRI, Inc., Massachusetts) was used (Supple-
mentary Figure 1B, http://links.lww.com/SLA/B84).20 Liver fat
was chemically quantified by the Vanillin method.21
Surgical Procedures
Isoflurane inhalation (2% to 4%) anesthesia (Pittman-Moore,
Chicago, IL) including subcutaneous injection of buprenorphine
(0.1mg/kg) was used for all surgical interventions. For ischemia/
reperfusion (I/R) experiments, 68% hepatic ischemia was induced as
described.22 Animals were sacrificed 6 hours after reperfusion, a time
point that well reflects injury levels at later reperfusion times.22
Hepatectomies (68% for normal liver regeneration, 86% for inducing
liver failure) were performed as reported.23 Omegaven (parenteral
fish oil emulsion; Fresenius Kabi AG, Oberdorf, Switzerland), was
intravenously (i.v.) injected 1 hour before hepatectomy at 0.2 g/kg.
Cell solutions (105/100ml phosphate-buffered saline [PBS]) of
exponentially growing MC-38 colorectal cancer cells were injected
into the portal vein under selective clamping as described,24 inducing
tumors limited to the right and caudate lobes.
Cell Culture
MC-38 cells were cultured as reported.24 Cultures were tested
negative for mycoplasma at their onset (PCR Mycoplasma Test Kit;
PromoCell Gmbh, Heidelberg, Germany).
Histological Analyses
Immunohistochemistry on archived liver sections was per-
formed for Ki67 (Abcam ab16667) and pH3 (Abcam ab92628) as
described.23 Quantification was done by blindly counting nuclear
positivity in 10 random visual fields.
Linecker et alSerum and Tissue Analysis
Serum alanine aminotransferase (ALT) and aspartate amino-
transferase (AST) levels were measured using a multiple
2 | www.annalsofsurgery.com
Copyright © 2016 Wolters Kluwer Health, Inc. Unbiochemical analyzer (Dri-Chem 4000i; Fujifilm, Tokyo, Japan).
Serum Hmgb1 levels were assessed by ELISA (Shino-Test, Japan,
via IBL International). The malondialdehyde assay (MDA) from
Oxis (Bioxytech #21012) was used to estimate lipid peroxidation.
Quantitative Real-Time PCR (qPCR)
Quantitative real-time polymerase chain reactions were run
on a ABI Prism 7000 Sequence Detector System (PE Applied
Biosystems, Rotkreuz, Switzerland) using following TaqMan gene
expression assays (PE Applied Biosystems, Rotkreuz, Switzerland):
Il1b (Mm00434228_m1), Emr1 (Mm00802530_m1), Tnfa
(Mm00443258_m1), and normalization control 18S rRNA.23
Statistical Analysis
Each group consisted of n ¼ 5 unless otherwise stated. Data
are presented as meanSD. Group differences were assessed by
Mann-Whitney testing throughout the manuscript. Survival was
assessed by Kaplan-Meier analysis. Significance levels are catego-
rized by stars (P < 0.05, P < 0.01, P < 0.001). Statistical
analyses were performed using GraphPad Prism 6.0 (GraphPad
Software, Inc., La Jolla, CA).
RESULTS
Equicaloric V3FA Substitution for the Reduction of
High Fat Diet Induced Steatosis
The experimental set up is shown in Figure 1A. Six weeks of
HFD feeding led to a gain in mean bodyweight from 21.5 g (1.3) to
34.3 g (2.9), rising to 40.6 g (3.9) after 10 weeks in the HFD
control group (Figure 1B). In the HFD-V3FA group, bodyweight
increased to 39.2 g (4.9) indicating that V3FA treatment has little
effect on diet-induced obesity (P ¼ 0.686). Liver weight grew from
0.9 g (0.1) to 1.8 g (0.2) after 6 weeks and 1.9 g (0.3) after
10 weeks in the HFD group, but was decreased by V3FA from 1.8 g
(0.2 g) to 1.5 g (0.1, P ¼ 0.016). Both groups had a comparable
food intake during treatment (HFD 360.4 g/cage vs HFD-V3FA
356.5 g/cage). On histology, lipid accumulation was seen in hepato-
cytes after 6 weeks of HFD. After 10 weeks, severe microsteatosis
with rare signs of macrosteatosis (lipid droplets, displaced hepato-
cyte nuclei) was present in the HFD group, while steatosis was
markedly diminished in the HFD-V3FA group and marginal in the
CD group (Figure 1C). Histology revealed no signs of fibrosis or
significant immune infiltration. No significant elevations in hepatic
lipid peroxidation, serum Hmgb1 levels, and inflammatory markers
were noted in the HFD group (Supplementary Figure 2, http://links.
lww.com/SLA/B84). Therefore, 10 weeks of HFD induce simple
steatosis in mouse liver.
Chemical analysis confirmed steatosis, with lipid contents
after 6 weeks being 41.1 (12.2) and 14.2mg/mg (2.4, P ¼ 0.002)
in liver tissue from HFD and CD animals, respectively (Figure 1D).
Similarly, liver fat assessed byMRI was significantly elevated after 6
weeks HFD compared with CD, further increased after 10 weeks of
HFD, but was drastically reduced in the HFD-V3FA group
(Figure 1D). Therefore, MRI was used to longitudinally monitor
steatotic development and treatment effects in vivo.
Altogether, our HFD mouse feeding protocol designed to
mimic western diet induces obesity and simple steatosis, while
CD feeding is associated with little gain in body or liver weight
[6 weeks: body 26.9 g (2.0)/liver 1.3 g (0.2); 10 weeks: 28.6
(2.6)/1.5 g (0.3); CD-V3FA 10 weeks: 30.9 (3.4)/1.2 g (0.1);
Annals of Surgery  Volume XX, Number X, Month 2016P¼ 0.530 for bodyweight, P¼ 0.111 for liverweight]. Four weeks of
V3FA treatment via dietary fat substitution are associated with
a reduction in steatosis to levels similar to those in CD-fed animals
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FIGURE 1. Antisteatotic effects of V3FA
in a model of HFD-induced fatty liver
disease. A, Experimental design showing
schedules of HFD/CD feeding and V3FA
treatment. Effects were assessed sub-
sequent to the treatment unless other-
wise stated. B, Body and liver weight
during the feeding and treatment
periods. C, Liver histology of mice
exposed to CD or HFD for 6 weeks, and
to another 4 weeks of HFD or HFD along
with V3FA substitution. Pale cytoplasmic
spots represent lipid vesicles. D, Chemical
analysis of hepatic fat content after differ-
ential feeding, and MRI assessment
of liver fat content after the feeding/
treatment period. For all figures: n ¼ 5/
group unless otherwise stated; P < 0.05,
P < 0.01, P < 0.001.
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Figure 1D], consistent with the reported V3FA-defattening
effects.7–11 Therefore, our HFD protocol yields a clinically relevant
model to study how pre-operative V3FA treatment impacts surgical
outcomes (I/R injury, liver regeneration, and malignant risk) com-
plicated through fatty liver.
V3FA Protect Fatty Liver Against Ischemia
Reperfusion
Steatosis increases the sensitivity of liver toward I/R.13 V3FA
can protect against I/R in genetic models of NAFLD; however,
whether protection can be also achieved in diet-induced steatosis
is unknown.
Following treatment, HFD and HFD-V3FA mice were
exposed to partial hepatic ischemia for 60minutes. Six hours after
reperfusion,22 liver injury was assessed via multiple parameters.
Necrosis on histology was visibly reduced in the HFD-V3FA versus
the HFD group (Figure 2A), as was sinusoidal plugging indicated by
stuck erythrocytes. Likewise, marked reductions through V3FA
treatment were noted for the injury markers ALT/AST, and for
Hmgb1, released by necrotic cells and propagating parenchymal
injury following reperfusion (Figure 2B).25 Therefore, V3FA treat-
ment of mouse liver with diet-induced steatosis offers effective
protection against hepatic I/R.
 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Health, Inc. UV3FA Accelerate the Regeneration of Fatty Liver
After Resection
Lipid accumulation in hepatocytes diminishes hepato-
regenerative capacities, thereby increasing the likelihood of
postoperative complications including liver failure.4,5 After 68%
hepatectomy (68%HX) in lean liver, the original liver weight is
gradually regained (by 50% after 48 hours, 70% after 96 hours) and
completely restored after 1 week.23 HFD-induced steatosis was
associated with a delayed liver weight regain after 68%HX (45%
after 48 hours, 50% after 96 hours). V3FA treatment improved
regeneration patterns to those seen in lean mice (50% after 48 hours,
70% after 96 hours), suggesting that V3FA can normalize regener-
ative capacity (Figure 3A). V3FA treatment also improved the
liver-to-body weight ratio (LW/BW) after resection (Figure 3A),
however less pronounced than for percentage increase, because
V3FA differentially affect liver versus body weight (Figure 1B).
Counts for Ki67, marking all cycling cells, were elevated in
the HFD-V3FA versus HFD group at most times examined after
68%HX (Figure 3B). To assess cell cycle progression, we examined
pH3, a differential marker for cells in the G2 (weak nuclear positivity)
and M (bold nuclear positivity) cell cycle phases.23 The ratio of bold
versus total pH3 counts thus reflects the proportion of mitotic cells
among cells past the S-phase. Compared with the HFD group,V3FA-
treated liver displayed a significantly increased pH3 ratio at 72 and
96 hours postresection (Figure 3C). Therefore, V3FA treatment of
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FIGURE 2. V3FA effects on I/R injury
in fatty liver 6 hours after reperfusion.
A, Histological necrosis. B, Serum ALT,
Linecker et al Annals of Surgery  Volume XX, Number X, Month 2016fatty liver promotes entry of hepatocytes into cell cycle and their
mitotic progression at times when hepatocellular division usually is
completed.23
V3FA Contribute to Hepatoprotection Also
Independent of Fat Reduction
To investigate whether the protection of fatty liver against I/R
through V3FA is solely due to steatosis reduction,26 experiments
were repeated in mice fed on CD for 6 weeks, and then exposed or not
to CD diet enriched in V3FA.
After 10 weeks feeding, CD mice present with little steatosis
in their liver (Figure 1C, D). Accordingly, a 4-week V3FA led to an
insignificant reduction in lipid content (Figure 4A). WhenV3FA-CD
animals were subjected to hepatic ischemia, injury levels were
reduced by about a half compared with the CD group (Figure 4B, C).
We conclude that in addition to the reduced sensitivity toward
I/R following fat reduction, V3FA also exert steatosis-independent
protection against hepatic ischemia.
V3FA Promote Liver Regeneration in a Direct Way
To determine whether V3FA can improve liver regeneration
also independent of fat reduction,26 CD-fed mice treated or not with
V3FA were subjected to 68%HX.
Regenerative improvements through V3FA were less pro-
B 3 3 nounced in lean versus fatty liver. The percentage gain in liver
weight was significantly raised by V3FA at 96 hours postresection
time, while LW/BW tended to be increased (Figure 5A). Ki67 and
4 | www.annalsofsurgery.com
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with more hepatocytes in cycle and with accelerated mitotic pro-
gression at 96 hours (Figure 5B, C). To provide additional evidence
for a pro-regenerative effect of V3FA in lean liver, we tested an
86%HX model of regenerative deficiency due to defective cell cycle
progression.23 V3FA (or vehicle12) were i.v. injected as an emulsion
(Omegaven) 1 hour before surgery to reveal their direct effects.
Examining 96 hours post 86%HX, when regeneration is most
delayed,23 Omegaven increased liver weight (Figure 5D), consistent
with a direct pro-regenerative effect on liver.
V3FA Counteract Colorectal Liver Metastases in a
Syngeneic Model
Given the pro-regenerative effects of V3FA, their impact on
liver malignancy was unclear.
To estimate potential effects of V3FA on hepatic malignancy,
we used a syngeneic, orthotopic mouse model of CRLM, wherein
MC-38 cancer cells are injected in the portal vein under selective
clamping, leading to lobe-restricted tumor growth that is the major
determinant of survival.24 We tested 2 settings (Figure 6A): the direct
impact of V3FA treatment on the establishment and growth of
CRLM (cancer cell injection before treatment), and the indirect
impact, that is, how CLRM development is affected after liver has
been treated withV3FA (injection after treatment, similar to surgery-
3 AST, and Hmgb1 levels.induced disease recurrence). Tumor inoculation before treatment led
to a median survival of 36 days (from injection) in HFD animals
(Figure 6B), with median liver weight at 4.3 g (1.4). In contrast,
 2016 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 3. V3FA effects on regeneration
of fatty liver after 68% hepatectomy. A,
Percent liver weight after hepatectomy in
HFD and HFD-V3FA mice. B, LW/BW
after hepatectomy. C, Percentage of
Ki67-positive hepatocytes after hepatec-
tomy. Photographs show representative
examples of Ki67 staining. D, Differential
pH3 counts after hepatectomy. The ratio
displays the number of hepatocytes with
bold pH3 staining (marking M cells, see
examples marked by arrows) divided by
the number of all pH3-positive cells
(marking G2 and M cells).
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Linecker et al Annals of Surgery  Volume XX, Number X, Month 2016survival in HFD-V3FA animals was 59 days (P ¼ 0.07) and liver
or CD-V3FA mice. B, Percentage of Ki67-positive hepatocytes
Arrows mark pH3-positive mitotic cells. D, Percent liver weight
without concomitant V3FA injection.weight 3.8 g (0.4), suggesting V3FA inhibit CRLM in pre-existing
steatosis. For tumor inoculation after treatment, survival after injec-
tion was 40 days [liver weight 5.2 g (1.7) in the HFD group and was
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Copyright © 2016 Wolters Kluwer Health, Inc. Unextended to 47 days (P ¼ 0.156; liver weight 5.6 g (1.1)] in the
r hepatectomy. C, Differential pH3 counts after hepatectomy.
LW/BW at 96hours after extended (86%) hepatectomy with/HFD-V3FA group (Figure 6C). To better assess the latter differences,
liver weight (n ¼ 3/group) was measured at day 30 postinjection
and was 2.9 g (0.5) for HFD and 1.5 g (0.3), P ¼ 0.100) for
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FIGURE 6. V3FA effects on CRLM in HFD
and CD liver. A, Selective portal vein injec-
tion of cancer cells and experimental
setup to estimate V3FA effects on CRLM.
B, Kaplan-Meier survival curves for HFD/
HFD-V3FA mice injected with cancer
cells before treatment. C, Survival for
HFD/HFD-V3FAmice injected with cancer
cells after treatment. D, Survival for
CD/CD-V3FA mice injected with cancer
A 
s
u
rv
iv
a
l 
[%
]
0
25
50
75
100 CD
CD n3-PUVA
MC-38 cell injection before treatment
s
u
rv
iv
a
l 
[%
]
0 20 40 60 80
0
25
50
75
100
days daysC 
s
u
rv
iv
a
l 
[%
]
0 20 40 60 80
0
25
50
75
100 HFD
HFD 3
s
u
rv
iv
a
l 
[%
]
0
25
50
75
100
B 
MC-38 cell injection after treatment
MC-38 cell injection before treatment MC-38 cell injection after treatment
tumor
free
tumor
laden 
Annals of Surgery  Volume XX, Number X, Month 2016 Omega-3 Fatty AcidsHFD-V3FA animals, indicating V3FA delay CRLM development as
confirmed on MRI (Supplementary Figure 3, http://links.lww.com/
SLA/B84). Therefore, V3FA maintain some anticancer effects in
liver also after treatment cessation.
Above experiments were repeated in mice on a CD. For
inoculation before treatment, survival was 35 days in CD and 46
days in CD-V3FA mice [P ¼ 0.027; liver weights 3.6 g (0.9) and
4.5 g (1.5), respectively]. For inoculation after treatment, survival
was 35 days in CD and 39 days in CD-V3FA mice [P ¼ 0.137; liver
weights 4.8 g (1.9) and 4.3 g (1.3), respectively]. Therefore,
V3FA may also inhibit CRLM in lean liver, albeit modestly.
cells before treatment. E, Survival for CD/
CD-V3FA mice injected with cancer cells
after treatment.
0 20
D We conclude that V3FA may exert anticancer effects on both
fatty and lean liver even beyond their administration. V3FA are
hence unlikely to compromise oncological outcomes in liver surgery.
DISCUSSION
In this study, we showed in a mouse model of HFD-induced
NAFLD that preoperative V3FA treatment confers several benefits
influencing the outcome of major surgery. We observed that steatotic
reduction associated with the use of V3FA has relevant positive
consequences on (i) the sensitivity of liver to I/R, (ii) its regenerative
capacity following tissue loss, and (iii) seemingly also on CRLM, a
prime indication for liver surgery. Furthermore, we found thatV3FA
maintain—at a smaller scale—these beneficial effects in the absence
of steatosis, indicating the mode of action of V3FA extends beyond
the sole reduction of fat. Therefore, V3FA may suit to expand the
application of liver surgery in situations of both fatty and nonfatty
liver surgery.
The health benefits of V3FA are manifold and cannot be
attributed to a single mechanism. Dietary V3FA comprise a number
 2016 Wolters Kluwer Health, Inc. All rights reserved.
Copyright © 2016 Wolters Kluwer Health, Inc. Uof fatty acids, ofwhichEPAandDHAare themajor constituents.Apart
from modulating the composition and function of cell membranes,
V3FA can activate specific receptors (eg, GPR12012) and are further
metabolized into a series of bioactive lipids (eg, resolvins, protectins),
which participate in cellular signaling and are intermingled with other
lipid signaling systems, such as by acting as ligands of cannabinoid-
type receptors.27,28 This underlying complexity suggests that detailed
action mechanisms of V3FAwill vary to provide dynamic responses
toward specific situations. More broadly, V3FA however do have
phenotypic effects thatmay be considered as general attributes of these
lipids. The anti-inflammatory action (eg, nuclear factor kappa-light-
chain-enhancer of activated B cells (NFkB) inhibition), the promotion
of a healthy endothelial phenotype (eg, NO production), and the
changes in energy turnover (eg, promotion of b-oxidation, inhibition
ofmammalian target of rapamycin [mTOR] signaling) reminiscent of a
fasting response (eg, activation of silent mating type information
regulation 2 homolog 1 [SIRT1], 50 adenosine monophosphate-acti-
vated protein kinase [AMPK]) likely are properties of V3FA that
contribute to their beneficial effects on steatosis, hepatic I/R, liver
regeneration, and cancer.9,29–32
Inflammation, endothelial dysfunction, and alterations in
oxidative metabolism have all been causally linked to steatosis.10,33,34
We have previously shown that relieving steatosis-associated vaso-
constriction via V3FA normalizes the oversensitivity toward I/R,13
while V3FA-GPR120 mediated inhibition of inflammatory Kupffer
cells protects lean liver akin to fasting.12,25 Endothelial effects clearly
will add, because sinusoids are the first to experience the consequences
of ischemia. Proper endothelial function likewise is a prerequisite
40 60 80 0 20 40 60 80
E for liver regeneration after resection,35 and the improvement of the
defective regeneration seen in aged liver is associated with the re-
installation of vascular integrity.36 How V3FA’s anti-inflammatory
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tumor necrosis factor (TNF) from Kupffer cells is needed for regen-
eration,37 but excess TNF, often elevated in fatty liver,38 causes liver
failure after hepatectomy.39 Furthermore, targeting inflammatory
Kupffer cells has a little effect on regeneration,40 suggesting that
inflammatory contributions to regeneration are more complex than
thought.
Inflammation and pathological angiogenesis are hallmarks of
cancer; the trend seen for V3FA in inhibiting CRLM is hence not
surprising.32,41 A tendency to prolonged survival through V3FAwas
observed in all 4 settings (HFD vs CD, injection before vs after
treatment) we tested, indicating that V3FA may be beneficial, but
certainly not harmful, with regard to CRLM. The largest effect on
survival was seen when cancer cells were injected before treatment,
thus when the early CRLM development was fully exposed toV3FA.
When injected after treatment, V3FA levels are expected to decline
over time, explaining their diminished ‘‘anticancer’’ effects. Of note,
survival in general was shortened in lean versus fatty liver, perhaps
suggesting an anti-malignant effect for steatosis. We speculate this
was due to better perfusion in lean liver,13 facilitating migration/
transport of cancer cells from the portal vein into the sinusoids and
thereby increasing the initial malignant load. Although controversial,
some clinical observations have reported a reduced incidence of
CRLM in steatotic patients and an improved survival in steatotic/
obese CRLM patients,42–45 consistent with steatosis creating a
microenvironment unfavorable to invasion and colonization of liver
by malignant intestinal cells.
Altogether, V3FA treatment of fatty and lean liver was
beneficial across the key aspects related to major liver surgery. To
foster a potential clinical application, we have initiated a clinical trial
(NCT01884948) to assess the impact of V3FA on outcomes after
major liver surgery. This study should also inform on the V3FA
activities in I/R, regeneration, and steatosis in patients.46
The use of V3FA as a measure to expand the application of
surgery to fatty liver, or lean liver requiring extended resection,
comes with several advantages; the pre-operative administration of
V3FA is simple, either as a food supplement or via intravenous
injection (Omegaven). Therefore, little issues with compliance are
expected, unlike for the currently recommended NAFLD treatment,
that is, exercise combined with caloric restriction.31 Given thatV3FA
are being ingested as part of our food and have been assessed in
various trials, potential side effects will not hamper their clinical
use.47 Indeed, prolonged application such as needed for ‘‘defat-
tening’’ may exert additional benefits, including the mitigation of
the MS, cardiovascular disease, or other comorbidities associated
with NAFLD.31 More research is needed to identify which of the
V3FA lipids and at what dosages may induce specific benefits in a
given setting.
In conclusion, our findings suggest a potential of V3FA in
extending surgical options for both fatty and lean livers. Apart from
the steatotic changes, the benefits of V3FA include an increased
tolerance toward ischemic reperfusion injury, an improved regener-
ative capacity, and a trend toward lower mortality due to liver tumors.
These effects partially are not only a consequence of the V3FA-
associated defattening but also occur in the absence of significant
steatosis, implying that the anti-inflammatory, vascular, and meta-
bolic effects of these lipids are likewise beneficial to physiological
liver function. Their ease of application, their safety profile, their
affordability, and their many potential health benefits with regard to
comorbidities or oncological indications advocate their use in the
Linecker et alclinic. Considering the endemic rise in fatty liver disease, V3FA-
based strategies hold a strong position in improving outcomes and
should be tested in convincing clinical studies.
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